Dishman Carbogen Amcis Limited owns CARBOGEN AMCIS whose Switzerland-based entity has announced two major expansion projects that will increase manufacturing capacity to meet the demands of the current market and its customers.
The new facilities, located in Switzerland and France, will be phased in over the next four years, with investments in excess of CHF 100 million (over €90 million), which will provide six years of constant growth for the company. This capital expenditure will be funded by way of debt and cash accruals at the company's subsidiaries.
In Switzerland, the project will be initiated in 2021 with the construction of a new API manufacturing facility at its Hunzenschwil site, which is planned to get operational by the summer of 2024. This project will progress in several phases. In addition to the new Swiss API manufacturing facility, additional investments are planned to improve some of the existing technologies and to increase the capacity of the current Swiss sites, such as adding chromatography equipment, new reactors in production along with new laboratories.
In France, on newly-acquired land located 7 km from an existing site in Riom, construction will begin in January 2021 for the manufacturing of parenteral drug products, whose operations will commence during Q1FY23. This facility will allow handling complex formulations, including a large range of different types of APIs from biologics to any kind of highly potent compounds. The new French site will be able to supply both clinical batches up to phase III and small-scale for commercial. There will be two automated lines: the first one for both liquid filling plus lyophilisation and the second one dedicated to liquid forms.
Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services located at Ahmedabad, India.
On Friday, the stock of Dishman Carbogen Amcis was up by 1.4 per cent to Rs 196.85 from its previous close of Rs 194.35 on BSE.